Page 2 - Upstream Processing News Today

Aldevron is expanding its mRNA production capabilities to include lipid nanoparticle (LNP) encapsulation and aseptic fill-finish capabilities.

Originally announced in 2021, the company expects the US facility for plasma treatments to be ready by the end of 2024.

Cytiva and the life sciences business of Pall Corporation are now united as one business under the Cytiva brand, with the completion of the integration announced this morning. Emmanuel Ligner, Danaher Group Executive, President and CEO of Cytiva, tells us how the company will focus its efforts moving forward to support long-term growth of the biotech industry.

Bristol Myers Squibb will boost its cell therapy manufacturing network with in-house viral vector production thanks to the acquisition of Novartis’ Libertyville, Illinois facility.

BioMarin Pharmaceutical has opened the expansion of its manufacturing plant at Shanbally, Co. Cork: with the site now able to provide end-to-end manufacturing for a number of the company’s commercial products.

CDMO Sterling Pharma Solutions has been granted a Manufacturer’s Authorisation for Investigational Medicinal Products from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA).

Asahi Kasei Bioprocess America and GeminiBio have entered into a strategic partnership to advance the application of inline buffer formulation (IBF) in the biopharmaceutical industry.

Dyadic extends its licensing agreement with Rubic for the use of its C1-cell protein expression platform.

The CDMO signs an exclusive partnership with the University of Pennsylvania to gain access to its cell manufacturing platform.

Avid Bioservices, a dedicated biologics CDMO in the US, has completed two expansions within the company’s mammalian cell facilities